Actively Recruiting
Phase 3 Study Comparing Intravenous Etentamig to Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma
Led by AbbVie · Updated on 2026-08-03
380
Participants Needed
166
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Multiple myeloma is a cancer affecting plasma cells in the bones and bone marrow, causing bone pain, fractures, infections, weak bones, and kidney failure. This study is evaluating the investigational drug etentamig compared to standard available therapies in adults with relapsed or refractory multiple myeloma. The study aims to understand changes in disease symptoms and treatment effects over time in this population. Participants are randomly assigned to one of two groups Arm A receives etentamig as an intravenous infusion given in 28-day cycles, and Arm B receives standard available therapies chosen by the investigator based on local guidelines. The study will last about 3.5 years, with treatments and monitoring continuing throughout this period. Participants will attend regular visits at hospitals or clinics for medical assessments, blood tests, side effect monitoring, and questionnaires. Researchers will measure outcomes such as progression-free survival, response rates, overall survival, symptom changes, and quality of life using questionnaires and clinical tests. The study includes careful safety monitoring and may involve more treatment visits than standard care.
CONDITIONS
Brief Title
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
